GlassScriptPhysician profile
Barbara Ann Violette
NPI 1174863351
$11,780.17
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,372 · 2022: $3,325 · 2023: $3,227 · 2024: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,048 · Education: $34.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,048.44 |
| Education | $34.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,472.79 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $1,213.85 | 2021-2024 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $835.22 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $826.20 | 2021-2024 | Rexulti, Abilify Asimtufii, Nuedexta |
| Janssen Pharmaceuticals, INC | $787.95 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $786.81 | 2021-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $775.06 | 2021-2024 | Rexulti |
| Corium, LLC | $673.31 | 2021-2024 | Azstarys, Adlarity |
| Ironshore Pharmaceuticals INC. | $523.27 | 2021-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $511.94 | 2021-2024 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $505.03 | 2021-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $466.20 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $430.56 | 2021-2023 | Belsomra |
| Supernus Pharmaceuticals, INC. | $286.66 | 2022-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $239.49 | 2021-2024 | Trintellix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $222.74 | 2022 | |
| Indivior INC. | $213.58 | 2021-2024 | Sublocade |
| Almatica Pharma LLC | $176.15 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $142.33 | 2023-2024 | Auvelity, Sunosi |
| Lilly USA, LLC | $124.99 | 2023 | Mounjaro |
| Jazz Pharmaceuticals INC. | $120.46 | 2021-2022 | |
| Tris Pharma INC | $116.62 | 2021-2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $90.71 | 2021 | |
| Idorsia Pharmaceuticals US INC | $81.74 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $43.06 | 2024 | Cobenfy |
| Noven Therapeutics, LLC | $27.85 | 2024 | Xelstrym |
| Neos Therapeutics, LP | $24.08 | 2021 | |
| Allergan, INC. | $23.65 | 2021 | |
| Eisai INC. | $21.49 | 2021 | |
| Tempus Ai, INC | $16.38 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Violette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.